Talphera Inc (TLPH)

$0.47 +0.03 (6.36%)
Market Cap 9.17M
Revenue (ttm) 0.00
Net Income (ttm) -13.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 164,215
Avg Vol 37,126
Day's Range N/A - N/A
Shares Out 20.50M
Stochastic %K 11%
Beta -0.11
Analysts Strong Sell
Price Target $3.25

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
bobmoney
bobmoney Jun. 27 at 6:56 PM
$TLPH Mid year -- next week -- Talphera Chief Medical Officer, a nephrologist trained doctor, you are 3 of 3 FDA AGREED to Phase 3 NEPHRO successful changes... keep the momentum going... !
0 · Reply
nazzangr
nazzangr Jun. 27 at 5:03 PM
$TLPH lol dont get your hopes up until the news... patiently waiting…
0 · Reply
bobmoney
bobmoney Jun. 27 at 4:21 PM
$TLPH ...heparin & citrate (2 bad anticoagulants) both on the FDA "short list"... Talphera's Niyad (if FDA approved) would be the only FDA approved anticoagulant for the Extracorporeal Circuit... think kidneys, heart, lungs... !
0 · Reply
bobmoney
bobmoney Jun. 27 at 3:31 PM
$TLPH I know there is nobody here, but so far Volume nearing -- 3x average 3 month Volume -- !
0 · Reply
bobmoney
bobmoney Jun. 25 at 11:09 PM
$TLPH Green close finally, oh my... lol New CMO...-- deliver --- !
0 · Reply
Crandaddy01
Crandaddy01 Jun. 25 at 2:56 PM
$TLPH
0 · Reply
bobmoney
bobmoney Jun. 24 at 8:19 PM
$TLPH Zero (0) expectations at this point! Albeit, wishful thinking -- positive Phase 3 news -- --- their Price Target now = 1,300% -- LOL!
0 · Reply
bobmoney
bobmoney Jun. 24 at 7:35 PM
$TLPH NEPHRO (Niyad Phase 3) patient enrollment update when from Talphera's new Chief Medical Officer; a nephrologist doctor by training... ???
0 · Reply
bobmoney
bobmoney Jun. 24 at 4:35 PM
$TLPH Mid-Year is next week... Talphera's new Chief Medical Officer (a nephrologist by training) identified the "new prodile sites:" 5 new profile sites expected mid year: - ICU Medical Centers. - Primary Investigators - nephrologists - 4 new profile sites Ph 3 enrolling underway: - ICU Medical Centers; nephrologist lead... - Total high Volume CRRT sites; 200 CRRT procedures per month. 4 Legacy sites - do not meet proiles.
0 · Reply
AlwaysRational
AlwaysRational Jun. 23 at 8:27 PM
$TLPH I'm back in with a small position at these levels. I still believe the CEO is bad at his job, which is why I'm not investing more heavily. But at these prices, it's worth a flier.
0 · Reply
Latest News on TLPH
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:01 PM EDT - 6 weeks ago

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 6 weeks ago

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025, 4:05 PM EDT - 7 weeks ago

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 6:33 PM EDT - 3 months ago

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 3 months ago

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Mar 31, 2025, 8:30 AM EDT - 3 months ago

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Mar 26, 2025, 4:38 PM EDT - 3 months ago

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Jan 14, 2025, 8:30 AM EST - 5 months ago

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:43 PM EST - 8 months ago

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 8 months ago

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Nov 6, 2024, 4:05 PM EST - 8 months ago

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:54 PM EDT - 9 months ago

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 4:15 PM EDT - 10 months ago

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Aug 19, 2024, 8:30 AM EDT - 11 months ago

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:39 PM EDT - 11 months ago

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 11 months ago

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Aug 5, 2024, 4:05 PM EDT - 11 months ago

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 20, 2024, 5:25 PM EDT - 1 year ago

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 1 year ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:21 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

May 2, 2024, 4:15 PM EDT - 1 year ago

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:48 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Mar 1, 2024, 7:30 AM EST - 1 year ago

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Feb 26, 2024, 4:15 PM EST - 1 year ago

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

Jan 18, 2024, 8:30 AM EST - 1 year ago

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

bobmoney
bobmoney Jun. 27 at 6:56 PM
$TLPH Mid year -- next week -- Talphera Chief Medical Officer, a nephrologist trained doctor, you are 3 of 3 FDA AGREED to Phase 3 NEPHRO successful changes... keep the momentum going... !
0 · Reply
nazzangr
nazzangr Jun. 27 at 5:03 PM
$TLPH lol dont get your hopes up until the news... patiently waiting…
0 · Reply
bobmoney
bobmoney Jun. 27 at 4:21 PM
$TLPH ...heparin & citrate (2 bad anticoagulants) both on the FDA "short list"... Talphera's Niyad (if FDA approved) would be the only FDA approved anticoagulant for the Extracorporeal Circuit... think kidneys, heart, lungs... !
0 · Reply
bobmoney
bobmoney Jun. 27 at 3:31 PM
$TLPH I know there is nobody here, but so far Volume nearing -- 3x average 3 month Volume -- !
0 · Reply
bobmoney
bobmoney Jun. 25 at 11:09 PM
$TLPH Green close finally, oh my... lol New CMO...-- deliver --- !
0 · Reply
Crandaddy01
Crandaddy01 Jun. 25 at 2:56 PM
$TLPH
0 · Reply
bobmoney
bobmoney Jun. 24 at 8:19 PM
$TLPH Zero (0) expectations at this point! Albeit, wishful thinking -- positive Phase 3 news -- --- their Price Target now = 1,300% -- LOL!
0 · Reply
bobmoney
bobmoney Jun. 24 at 7:35 PM
$TLPH NEPHRO (Niyad Phase 3) patient enrollment update when from Talphera's new Chief Medical Officer; a nephrologist doctor by training... ???
0 · Reply
bobmoney
bobmoney Jun. 24 at 4:35 PM
$TLPH Mid-Year is next week... Talphera's new Chief Medical Officer (a nephrologist by training) identified the "new prodile sites:" 5 new profile sites expected mid year: - ICU Medical Centers. - Primary Investigators - nephrologists - 4 new profile sites Ph 3 enrolling underway: - ICU Medical Centers; nephrologist lead... - Total high Volume CRRT sites; 200 CRRT procedures per month. 4 Legacy sites - do not meet proiles.
0 · Reply
AlwaysRational
AlwaysRational Jun. 23 at 8:27 PM
$TLPH I'm back in with a small position at these levels. I still believe the CEO is bad at his job, which is why I'm not investing more heavily. But at these prices, it's worth a flier.
0 · Reply
bobmoney
bobmoney Jun. 23 at 2:17 PM
$TLPH --- now we wait for a Press Release confirming the Phase 3 enrollment numbers--- Hopefully, good!
0 · Reply
bobmoney
bobmoney Jun. 23 at 3:43 AM
$TLPH My thinking, Pfizer would be wise to buy Talphera...& Pfizer would then have Talphera's Niyad (if FDA approved): --- the 1st FDA approved anticoagulant for the extracorporeal circuit --- Pfizer's heparin...an awful anticoagulant... !
0 · Reply
bobmoney
bobmoney Jun. 21 at 3:00 AM
$TLPH almost -- all -- biotech-pharma bad wk... My LLY even down 5% this wk... !
0 · Reply
bobmoney
bobmoney Jun. 20 at 11:27 PM
$TLPH -- both heparin & citrate shortages -- Listed shortage on the FDA website...both awful anticoagulants.. Holding my Talphera position... !
0 · Reply
bobmoney
bobmoney Jun. 20 at 1:43 PM
$TLPH --- LEU --- Oh my
0 · Reply
bobmoney
bobmoney Jun. 19 at 4:52 PM
$TLPH Talphera's Niyad (if FDA approved) would be the 1st FDA approved anticoagulant for use in the extracorporeal circuit! "The extracorporeal circuit is a critical component in various life-sustaining medical procedures, acting as an external circulatory system to support or replace the function of vital organs." !
0 · Reply
bobmoney
bobmoney Jun. 19 at 4:43 PM
$TLPH Know soon how it all plays out... What we do know, Talphera's new Chief Medical Officer (a nephrologist by training) is and has been a game changer with the -- recent Phase 3 FDA agreed to trial changes -- !
0 · Reply
bobmoney
bobmoney Jun. 19 at 4:39 PM
$TLPH LEU my current capital gain machine... TLPH upcoming Phase 3 milestones... If Niyad is FDA approved... a game changer...if not, so be it! !
0 · Reply
FKYOUSPIRIT
FKYOUSPIRIT Jun. 19 at 12:54 PM
$TLPH It simply amazes me how You wasted your life away here everyday, after losing 99.99% You have had several different names over the years, but everyone on Stocktwits know your Original name “GreatDayforInvesting” You never seeked any professional help for your addiction. Very sad
0 · Reply
bobmoney
bobmoney Jun. 17 at 4:00 PM
$TLPH As most know, Talphera's Niyad (NEPHRO Phase 3 trial) active ingredient -- nafamostat -- (new to the United States thanks to Talphera) used in Japan & South Korea over 30-years Safely & Effectively in - Renal hemodialysis - Cardiopulmonary bypass surgery. Also used in these indications: - Acute pancreatitis - Disseminated intravascular coagulation !
0 · Reply
bobmoney
bobmoney Jun. 17 at 3:46 PM
$TLPH CEO -- down -- over 20% on most recent purchase of ---- 213,310 shares @ $.59 ---- !
0 · Reply
bobmoney
bobmoney Jun. 16 at 9:27 PM
$TLPH -- 1,200% Target Price -- Talphera new Chief Medical Officer (nephrologist by training)... keep being -- brilliant -- with the Phase 3 trial... Commpassionate Use IDE... FDA win would be nice too... !
0 · Reply